Denali Therapeutics Inc.
DNLI
$14.12
-$0.20-1.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.87% | -7.05% | -8.25% | 2.73% | 14.79% |
| Total Depreciation and Amortization | 160.82% | -332.75% | 16.84% | -10.18% | -0.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.51% | 66.94% | 10.05% | 666.28% | -85.69% |
| Change in Net Operating Assets | -307.80% | -65.22% | 471.99% | 48.39% | -370.30% |
| Cash from Operations | -57.04% | -41.56% | 35.17% | 19.71% | -15.17% |
| Capital Expenditure | 0.27% | -31.10% | 18.85% | -122.60% | 3.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -86.56% | 81.77% | -5.63% | 122.91% | -699.13% |
| Cash from Investing | -89.11% | 83.87% | -4.99% | 121.75% | -720.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 47.65% | 65.34% | -- | -- | -- |
| Issuance of Common Stock | -85.68% | -30.00% | -12.14% | -98.65% | 10,543.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | 9.74% | 77.54% | -374.70% | -98.65% | 10,532.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -238.14% | 428.45% | 13.13% | 121.20% | -218.26% |